Podcast
MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper
The ULTIMATE Checklist for New MSLs
Summary
In this episode, Samantha Buckley discusses her journey from clinical pharmacy to becoming an MSL, highlighting the value of personalized cover letters and MSL certification. She delves into territory mapping, strategic planning, and the art of relationship-building as key components of the MSL role. Samantha emphasizes the importance of effective KOL meetings and the insights they provide. She also touches on cross-functional collaboration within Medical Affairs and shares the rewarding aspects of being an MSL. The episode concludes with encouragement for aspiring MSLs and closing remarks.
My guest this week is Samantha Buckley, PharmD. Medical Science Liaison at SOBI who discusses the ultimate checklist for new MSLs.
Learn more about…
π The ONE differentiating factor to her MSL job search success
π What is day one like for an MSL
π Training and certification
π The ART of MSLing
π Prep for initial KOL meetings
MSL, Medical Science Liaison, Samantha Buckley, KOL meetings, MSL certification
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper
Podcast
MSL Talk: Tom Caravela, Sarah Snyder
Surround to Succeed: Building a Motivational Network
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary